KalVista Pharmaceuticals ( (KALV) ) has provided an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
KalVista Pharmaceuticals has secured a significant up to $184 million synthetic royalty financing deal with DRI Healthcare Trust to fund the commercialization of sebetralstat, a novel oral therapy for hereditary angioedema (HAE). The agreement includes an initial $100 million upfront payment, potential milestone payments, and a tiered royalty structure based on global net sales. This strategic move strengthens KalVista’s financial position as it prepares for the anticipated U.S. launch of sebetralstat in 2025, potentially revolutionizing HAE treatment with an on-demand oral option.
See more data about KALV stock on TipRanks’ Stock Analysis page.
